Palivizumab in children with neurological disorders.

Prophylaxis with palivizumab is recommended for the prevention of serious lower respiratory tract diseases caused by RSV during anticipated periods of RSV infection risk in: Patients under 3 years of age affected by neuromuscular diseases with marked hypotonia and/or respiratory muscle weakness. Patients under 3 years of …